Cerevel Therapeutics Holdings Inc (FRA:673)
€ 23.6 0 (0%) Market Cap: 7.57 Bil Enterprise Value: 7.13 Bil PE Ratio: 0 PB Ratio: 14.49 GF Score: 20/100

Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) Transcript

Mar 29, 2023 / 02:30PM GMT
Release Date Price: €21.8 (+1.87%)
Paul Matteis
Stifel Financial Corp. - Analyst

Great. Thanks very much. It's my pleasure to be moderating this chat with Tony Coles, CEO of Cerevel. Tony, it's always great to see you.

We'll have a lot of specific stuff to get into. But maybe we can start with you just giving a quick update on the R&D portfolio, specifically the muscarinic, and then we can get into Q&A. So thanks again.

Tony Coles
Cerevel Therapeutics Holdings, Inc. - Chairperson of the Board of Directors & CEO

Well, Paul, always good to be with you. Thank you for having us. Look, the emraclidine program suggests us to start -- there is -- it's doing very, very well. We are currently enrolling the two large Phase 2s. They're still on track for a data readout in the first half of 2024.

Really importantly, for that particular program, we finished the very important risk-reducing trial, which was to look at this question of elevation in blood pressure. And that was clean, read out positively at the end of last year. So we're really encouraged by that.

We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot